Parikh V, Singh M
Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India.
J Cardiovasc Pharmacol. 1998 May;31(5):779-85. doi: 10.1097/00005344-199805000-00018.
This study was designed to investigate the effect of disodium cromoglycate (DSCG), a mast cell stabilizer, on cardioprotective effect of ischemic preconditioning. Isolated rat heart was subjected to 30 min of global ischemia followed by 30 min of reperfusion. Ischemic preconditioning was provided by four episodes of 5-min global ischemia followed by 5 min of reperfusion before sustained ischemia. Ischemic preconditioning and DSCG (10 and 100 microM) treatment markedly decreased the release of lactate dehydrogenase (LDH) and creatine kinase (CK) in coronary effluent and percentage incidence of ventricular premature beats (VPBs) and ventricular tachycardia/fibrillation (VT/VF) during reperfusion. Ischemic preconditioning and DSCG treatment also significantly reduced ischemia/reperfusion-induced mast cell peroxidase (MPO) release, a marker of mast cell degranulation. A significant increase in MPO release was observed immediately after ischemic preconditioning, and the release was found to be inhibited in hearts perfused with DSCG (10 and 100 microM) during ischemic preconditioning. DSCG administered during ischemic preconditioning (DSCG in ischemic preconditioning) attenuated the cardioprotective and antiarrhythmic effects of ischemic preconditioning. DSCG in ischemic preconditioning produced no marked effect on ischemia/reperfusion-induced MPO release. These findings tentatively suggest that DSCG administration during ischemic preconditioning abolishes its cardioprotective effect, perhaps by stabilizing resident cardiac mast cells.
本研究旨在探讨肥大细胞稳定剂色甘酸钠(DSCG)对缺血预处理心脏保护作用的影响。将离体大鼠心脏进行30分钟全心缺血,随后再灌注30分钟。缺血预处理通过在持续缺血前进行4次5分钟全心缺血,随后再灌注5分钟来实现。缺血预处理和DSCG(10和100微摩尔)处理显著降低了冠脉流出液中乳酸脱氢酶(LDH)和肌酸激酶(CK)的释放,以及再灌注期间室性早搏(VPB)和室性心动过速/心室颤动(VT/VF)的发生率。缺血预处理和DSCG处理还显著减少了缺血/再灌注诱导的肥大细胞过氧化物酶(MPO)释放,MPO释放是肥大细胞脱颗粒的标志物。缺血预处理后立即观察到MPO释放显著增加,并且发现在缺血预处理期间用DSCG(10和100微摩尔)灌注的心脏中MPO释放受到抑制。在缺血预处理期间给予DSCG(缺血预处理中的DSCG)减弱了缺血预处理的心脏保护和抗心律失常作用。缺血预处理中的DSCG对缺血/再灌注诱导的MPO释放没有显著影响。这些发现初步表明,缺血预处理期间给予DSCG可能通过稳定心脏固有肥大细胞而消除其心脏保护作用。